Switch to optionsXpress for advanced derivatives trading & earn 50 commission-free trades.
Advertisement
SureTrader Stock Hero Advertisement
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 3/31/2015 12:13:35 AM - Followers: 1221 - Board type: Free - Posts Today: 1
PostSubject
#189382  Sticky Note OCRX Outcomes Table for DSMB Actions in STOP-HE DewDiligence 03/30/15 03:43:01 PM
#189355  Sticky Note Aduro, NVS ink immuno-oncology collaboration: DewDiligence 03/30/15 10:31:39 AM
#189354  Sticky Note XON +6% on CAR-T deal with Merck Serono: DewDiligence 03/30/15 10:22:38 AM
#189338  Sticky Note HZNP acquires HPTX for $46/sh in cash—an 8% DewDiligence 03/30/15 08:53:40 AM
#189335  Sticky Note TEVA acquires ASPX for $101.00/sh in cash—a 42% DewDiligence 03/30/15 08:19:09 AM
#189175  Sticky Note …one thing i think ENTA should not DewDiligence 03/25/15 07:28:19 PM
#189407   Biotech Bull Rush!!! It's all about biotech stocks Stock Trading Guru 03/31/15 12:13:35 AM
#189406   >FGEN The trouble with fibrosis is that the end biomaven0 03/30/15 10:22:35 PM
#189405   >>time to event trial designs biomaven0 03/30/15 10:19:33 PM
#189404   Dew Diligence geocappy1 03/30/15 09:54:54 PM
#189403   Here's an extract from the registration statement for biomaven0 03/30/15 09:48:09 PM
#189402   FGEN: Just speculating the way the question was answered ghmm 03/30/15 08:41:44 PM
#189401   thx masterlongevity 03/30/15 08:25:56 PM
#189400   FDA approves NVS’ Jadenu—an enhanced formulation of Exjade DewDiligence 03/30/15 08:15:17 PM
#189399   For #1, check the Xgeva dossier. There may DewDiligence 03/30/15 08:10:09 PM
#189398   TRIL—They specifically say the 5% threshold is the DewDiligence 03/30/15 08:07:37 PM
#189397   time to event trial designs: open questions masterlongevity 03/30/15 07:43:56 PM
#189396   It's an non-event in my book, there's no jbog 03/30/15 07:00:15 PM
#189395   I haven't seen the details, but certainly I biomaven0 03/30/15 06:45:12 PM
#189394   TRIL—The reporting-requirement argument doesn’t really hold water; any DewDiligence 03/30/15 06:35:18 PM
#189393   >>(TRIL) Selling new preferred stock will only make biomaven0 03/30/15 06:28:17 PM
#189392   FDA expands use of CoreValve System jimmybob 03/30/15 05:40:36 PM
#189390   MYL -3% is not a bad day under DewDiligence 03/30/15 05:17:19 PM
#189389   RPTP, CERU, INSM selling shares: DewDiligence 03/30/15 04:23:59 PM
#189388   TRIL ought to be simplifying its capital structure, DewDiligence 03/30/15 04:14:33 PM
#189387   Yes, but this was known for over a ronpopeil 03/30/15 04:11:39 PM
#189386   TRIL selling $50M of common & preferred stock, DewDiligence 03/30/15 04:09:43 PM
#189385   It's my best guess based on experience. Nothing DewDiligence 03/30/15 04:09:11 PM
#189384   Re: OCRX Outcomes Table WorstLuck 03/30/15 04:05:29 PM
#189383   Dumb as a Rock "ModernRock" shorts SRPT on Double_Bagel 03/30/15 03:45:42 PM
#189382   OCRX Outcomes Table for DSMB Actions in STOP-HE DewDiligence 03/30/15 03:43:01 PM
#189381   OCRX—More useful are what is the chance for DewDiligence 03/30/15 03:42:42 PM
#189380   Thank you for sharing info on OCRX. WID 03/30/15 03:42:28 PM
#189379   In a rare misstep, the headline of that north40000 03/30/15 03:38:58 PM
#189378   SGYP - iandy 03/30/15 03:27:36 PM
#189377   (OCRX)—It’s an enigma that HTPX wanted to run DewDiligence 03/30/15 03:25:10 PM
#189376   Musings on the 60-Minutes glioblastoma treatment: DewDiligence 03/30/15 03:17:10 PM
#189375   In context it has been a little tepid north40000 03/30/15 03:13:09 PM
#189374   PBM consolidation will boost payers’ leverage (duh): DewDiligence 03/30/15 03:13:03 PM
#189373   Re: PBM consolidation DewDiligence 03/30/15 03:08:15 PM
#189372   Tepid not so much in absolute terms, but DewDiligence 03/30/15 02:57:33 PM
#189371   Addendum: Aduro’s deal with NVS is so lucrative DewDiligence 03/30/15 02:55:20 PM
#189370   XON: I do not think the reaction was north40000 03/30/15 02:50:08 PM
#189369   MultiVir—yet another gene-therapy company—files for IPO: DewDiligence 03/30/15 02:08:37 PM
#189368   Often the reason for dropping coverage of several DewDiligence 03/30/15 02:01:34 PM
#189367   Ariad- interesting move by Citi- dougheuring ?@dougheuringaria biotech_researcher 03/30/15 01:25:25 PM
#189366   HZNP-HPTX merger slides: DewDiligence 03/30/15 12:31:11 PM
#189365   You really think ABBV has the loss of DewDiligence 03/30/15 12:19:58 PM
#189364   ABBV had a similar problem with Humira, but jbog 03/30/15 12:04:48 PM
#189363   Teva is desperate to fix its overreliance on DewDiligence 03/30/15 11:18:21 AM
#189362   in relation to that, look at todays aquisition lgonber 03/30/15 11:11:46 AM
#189360   AEGR adds BoD member from Sarissa Capital: DewDiligence 03/30/15 10:51:42 AM
#189359   IMGN monetizes Kadcyla royalty stream for $200M: DewDiligence 03/30/15 10:49:02 AM
#189358   BDSI -27% on failure of phase-3 trial in DewDiligence 03/30/15 10:44:48 AM
#189357   CANF -57% on failure of phase-2/3 trial in psoriasis: DewDiligence 03/30/15 10:41:32 AM
#189356   Commentaries on Aduro-NVS deal: DewDiligence 03/30/15 10:38:00 AM
PostSubject